Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Drug Eluting Stent for High Risk Patients
Health Technologies at Strathclyde United Kingdom flag United Kingdom
Abstract ID:
A novel proprietary compound shown to be released from coatings on coronary artery stents to reduce restenosis without impairing blood vessel functio...
Contact
Participants
You
Email me a copy of this message

Background


Stent implantation is a highly effective treatment for restoring blood flow through an atherosclerotic artery; however restenosis (a re-narrowing of the diseased artery) occurs in a significant proportion of patients. Drug-eluting stents have been developed to limit restenosis and although they represent a major advance, they have limited effectiveness in diabetic patients. In addition, the drugs that are used at present inhibit the regrowth of the endothelium which is required to protect the artery. Thus, there is a need for an improved drug-eluting stent that will be suitable for diabetic patients, will not harm the endothelium, and will protect against blood clotting.


 


Technology


Using an in vivo model, researchers at the University of Strathclyde have found that restenosis can be prevented by a novel, proprietary compound with no harmful effects on endothelial properties. VAN 10-4, a novel small molecule, exerts a marked protection against the development of restenosis when applied as a drug-eluting stent or given as a short-term local infusion. VAN 10-4's superior activity is not confined to its ability to reduce neointimal formation; in vitro studies also showed that VAN 10-4 had no detrimental effect on contractile or relaxant function of blood vessels. VAN 10-4 is significantly more effective as an inhibitor of smooth muscle cell proliferation than paclitaxel. Furthermore, VAN 10-4 is equally effective at inhibiting p42/p44 MAPK activation in human and porcine artery cells, suggesting that its effects should be evident in the clinical setting. The use of VAN 10-4 on a drug-eluting stent holds great promise as a superior stent for high risk patients.


 


Key Benefits


·         Prevention of restenosis in artery stents


·         Designed for diabetic and high risk patients


·         Novel anti-proliferative mechanism


·         No detrimental effects on endothelial cell function or artery contractility


·         Enhanced efficacy and reduced toxicity compared with competitor compounds


·         Compound has cleared regulatory toxicology (data available)


Markets and Applications


This technology can be used for any procedure which carries the risk of restenosis, from angioplasty to artery reconstruction, for medical and pharmaceutical markets.


The worldwide coronary stent market is worth over $7 billion and is forecast to grow by more than 5% annually. The drug-eluting stent market was valued at $4.6 billion in 2010 and is expected to grow by 4.3% annually until 2017. The opportunity for a novel drug-eluting stent with superior performance to competitor products is high.


 

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

Contact is welcomed from organisations interested in developing, licensing or exploiting this technology

FEATURED
Last Updated Oct 2013
Technology Type
Phase of Development EARLY STAGE
UNIVERSITY